Detalhe da pesquisa
1.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
2.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
3.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
4.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
5.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
6.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
7.
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
J Clin Microbiol
; 60(4): e0228321, 2022 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35321556
8.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
9.
A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection.
Malar J
; 16(1): 107, 2017 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270152
10.
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Lancet Infect Dis
; 23(8): 956-964, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060917
11.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 40(35): 5248-5262, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35715352
12.
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics.
Front Immunol
; 13: 984323, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072606
13.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
; 7(7)2022 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192543
14.
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.
Vaccines (Basel)
; 9(3)2021 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33809415
15.
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS).
Vaccines (Basel)
; 9(8)2021 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34451976
16.
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Nat Commun
; 12(1): 4636, 2021 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34330906
17.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Nat Commun
; 12(1): 5861, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615860
18.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Lancet HIV
; 8(8): e474-e485, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34153264
19.
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Med
; 2(6): 701-719.e19, 2021 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34223402
20.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(2): 279-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335322